Substituted N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein
In one aspect, the disclosure relates to substituted N-(2-(2,6-dioxopiperidinyl-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfo namide analogs that useful as modulators of cereblon (CRBN) activity, methods of making same, pharmaceutical compositions comprising same, and methods of treating various clinical conditions and disorders using same, e.g., a disorder of uncontrolled cellular proliferation, such as a cancer, which may be associated with cereblon protein dysfunction and/or a GSPT1 dysfunction. In various further aspects, the disclosed compounds can selectively modulate the degradation of GSPT1 protein, i.e., the disclosed compounds can act as GSPT1 degraders. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
1. A compound having a structure represented by a formula:
wherein n is an integer selected from 0, 1 and 2;
wherein each of A 1 and A 2 is independently selected from —(C═O)— and —CH 2 —, provided that at least one of A 1 and A 2 is —(C═O)—;
wherein R 1 is selected from:
(a) a 5- to 10-membered aryl or heteroaryl optionally substituted with a group selected from halogen, —SF 5 , —CN, —N 3 , —NH 2 , —OH, —CN, —SCF 3 , C 1 -C 3 alkoxy, C 1 -C 3 haloalkyl, C 1 -C 3 aminoalkyl, C 1 -C 3 alkylamino, C 1 -C 3 hydroxyalkyl, —O—(C 1 -C 3 haloalkyl), C 3 -C 8 cycloalkyl, C 1 -C 6 alkyl, and phenyl; and
(b) a 5- to 10-membered cycloalkyl optionally substituted with a group selected from halogen, —SF 5 , —CN, —N 3 , —NH 2 , —OH, —CN, —SCF 3 , C 1 -C 3 alkoxy, C 1 -C 3 haloalkyl, C 1 -C 3 aminoalkyl, C 1 -C 3 alkylamino, C 1 -C 3 hydroxyalkyl, —O—(C 1 -C 3 haloalkyl), C 3 -C 8 cycloalkyl, C 1 -C 6 alkyl, and phenyl;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein n is selected from 0 and 1.
3. The compound of claim 1 , wherein each of A 1 and A 2 is —(C═O)—.
4. The compound of claim 1 , wherein the compound has a structure represented by a formula
wherein n is an integer selected from 0, 1 and 2;
wherein each of A 1 and A 2 is independently selected from —(C═O)— and —CH 2 —, provided that at least one of A 1 and A 2 is —(C═O)—;
wherein each of R 11 , R 12 , R 13 , R 14 , and R 15 is independently selected from hydrogen, halogen, —SF 5 , —CN, —N 3 , —NH 2 , —OH, —CN, —SCF 3 , C 1 -C 3 alkoxy, C 1 -C 3 haloalkyl, C 1 -C 3 aminoalkyl, C 1 -C 3 alkylamino, C 1 -C 3 hydroxyalkyl, —O—(C 1 -C 3 haloalkyl), C 3 -C 8 cycloalkyl, C 1 -C 6 alkyl, and phenyl;
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 4 , wherein at least one of R 11 and R 15 is not hydrogen.
6. The compound of claim 1 , wherein the compound has a structure represented by a formula:
wherein R 1a is selected from bromo, methyl, —CF 3 , and —OCF 3 ;
wherein each of R 1b , R 1d , and R 1e is independently selected from hydrogen, halogen, and methyl; and
wherein R 1c is selected from hydrogen, halogen, methyl, and phenyl;
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 6 , wherein R 1a is selected from —CF 3 and —OCF 3 .
8. The compound of claim 6 , wherein each of R 1b , R 1c , R 1d , and R 1e is hydrogen.
9. The compound of claim 1 , having a structure represented by a formula selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
10. The compound of claim 9 , having a structure represented by a formula selected from the group consisting of:
and
or a pharmaceutically acceptable salt thereof.
11. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , and a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
12. The pharmaceutical composition of claim 11 , further comprising at least one agent known to treat a cancer.
13. A method for amelioration or alleviation of a cancer characterized by GSPT1 activity in a mammal comprising a step of administering to the mammal a therapeutically effective amount of at least one compound of claim 1 , or a pharmaceutically acceptable salt thereof, thereby ameliorating or alleviating the cancer characterized by GSPT1 activity.
14. The method of claim 13 , wherein the mammal has been diagnosed with a need for treatment of the cancer prior to the step of administering to the mammal the therapeutically effective amount of the at least one compound.
15. The method of claim 13 , further comprising a step of identifying a mammal in need of treatment of the cancer.
16. The method of claim 13 , wherein the cancer is selected from a group consisting of brain cancer, lung cancer, hematological cancer, bladder cancer, colon cancer, cervical cancer, ovarian cancer, squamous cell cancer, kidney cancer, peritoneal cancer, breast cancer, gastric cancer, colorectal cancer, prostate cancer, pancreatic cancer, genitourinary tract cancer, lymphatic system cancer, stomach cancer, larynx cancer, malignant melanoma, endometrial carcinoma, thyroid cancer, rhabdosarcoma, leukemia, and combinations thereof.
17. The method of claim 16 , wherein the cancer is selected from a group consisting of leukemia, lung cancer, hematological cancer, bladder cancer, ovarian cancer, squamous cell cancer, breast cancer, prostate cancer, pancreatic cancer, genitourinary tract cancer, malignant melanoma, endometrial carcinoma, and combinations thereof.
18. The method of claim 17 , wherein the lung cancer is selected from a group consisting of small-cell lung cancer, non-small cell lung cancer, and combinations thereof;
wherein the bladder cancer is a bladder urothelial carcinoma; and
wherein the hematological cancer is selected from a group consisting of a childhood acute leukemia (AL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), acute lymphoid leukemia (ALL), hairy cell leukemia, chronic myelomonocytic leukemia (CMML), juvenile myelomonocyte leukemia (JMML), large granular lymphocytic leukemia (LGL), acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, hairy cell lymphoma, Burkett's lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, and combinations thereof.
19. The method of claim 13 , further comprising a step of administering a therapeutically effective amount of at least one agent known to treat a cancer.
20. The method of claim 19 , wherein the at least one agent is selected from a group consisting of uracil mustard, chlormethine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, pipobroman, triethylenemelamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, temozolomide, thiotepa, altretamine, methotrexate, 5-fluorouracil, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, pentostatin, bortezomib, vinblastine, vincristine, vinorelbine, vindesine, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, dexamethasone, clofarabine, cladribine, pemextresed, idarubicin, paclitaxel, docetaxel, ixabepilone, mithramycin, topotecan, irinotecan, deoxycoformycin, mitomycin-C, L-asparaginase, interferons, etoposide, teniposide 17a-ethinylestradiol, diethylstilbestrol, testosterone, prednisone, fluoxymesterone, dromostanolone propionate, testolactone, megestrolacetate, tamoxifen, methylprednisolone, methyltestosterone, prednisolone, triamcinolone, chlorotrianisene, hydroxyprogesterone, aminoglutethimide, estramustine, medroxyprogesteroneacetate, leuprolide, flutamide, toremifene, goserelin, cisplatin, carboplatin, hydroxyurea, amsacrine, procarbazine, mitotane, mitoxantrone, levamisole, navelbene, anastrazole, letrazole, capecitabine, reloxafine, droloxafine, hexamethylmelamine, oxaliplatin, gefinitib, capecitabine, erlotinib, azacitidine, temozolomide, gemcitabine, vasostatin, and combinations thereof.
21. The method of claim 19 , wherein the at least one agent is selected from a group consisting of a DNA methyltransferase inhibitor, an HDAC-inhibitor, a glucocorticoid, an mTOR inhibitor, a cytotoxic agent, and combinations thereof.
22. The method of claim 21 , wherein the DNA methyltransferase inhibitor is selected from a group consisting of 5-aza-2’-deoxycytidine, 5-azacytidine, zebularin, epigallocatechin-3-gallate, procaine, and combinations thereof;
wherein the HDAC-inhibitor is selected from a group consisting of vorinostat, entinostat, pan binostat, trichostatin A, mocetinostat, belinostat, dacinostat, givinostat, tubastatin A, pracinostat, droxinostat, quisinostat, romidepsin, valproic acid, AR-42 (OSU-HDAC42), tacedinaline, rocilinostat, apicidin, and combinations thereof;
wherein the glucocorticoid is selected from a group consisting of dexamethasone, prednisolone, methylprednisolone, betamethasone, triamicinolone, fludrocortisone, beclomethasone, and combinations thereof;
wherein the mTor inhibitor is selected from a group consisting of BEZ235, everolimus, temsirolimus, rapamycin, AZD8055, and combinations thereof; and
wherein the cytotoxic agent is selected from a group consisting of an alkylating agent, an antimetabolite agent, an antineoplastic antibiotic agent, a mitotic inhibitor agent, a mTor inhibitor agent, and other chemotherapeutic agent.
23. The method of claim 22 , wherein the antineoplastic antibiotic agent is selected from a group consisting of doxorubicin, mitoxantrone, bleomycin, daunorubicin, dactinomycin, epirubicin, idarubicin, plicamycin, mitomycin, pentostatin, valrubicin, and combinations thereof, or a pharmaceutically acceptable salt, hydrate, solvate, or polymorph thereof;
wherein the antimetabolite agent is selected from a group consisting of gemcitabine, 5- fluorouracil, capecitabine, hydroxyurea, mercaptopurine, pemetrexed, fludarabine, nelarabine, cladribine, clofarabine, cytarabine, decitabine, pralatrexate, floxuridine, methotrexate, thioguanine, a combinations thereof, or a pharmaceutically acceptable salt, hydrate, solvate, or polymorph thereof;
wherein the alkylating agent is selected from a group consisting of carboplatin, cisplatin, cyclophosphamide, chlorambucil, melphalan, carmustine, busulfan, lomustine, dacarbazine, oxaliplatin, ifosfamide, mechlorethamine, temozolomide, thiotepa, bendamustine, streptozocin, and combinations thereof, or a pharmaceutically acceptable salt, hydrate, solvate, or polymorph thereof;
wherein the mitotic inhibitor agent is selected from a group consisting of irinotecan, topotecan, rubitecan, cabazitaxel, docetaxel, paclitaxel, etopside, vincristine, ixabepilone, vinorelbine, vinblastine, teniposide, and combinations thereof, or a pharmaceutically acceptable salt, hydrate, solvate, or polymorph thereof;
wherein the mTor inhibitor is selected from a group consisting of everolimus, sirolimus, temsirolimus, and combinations thereof; and
wherein the other chemotherapeutic agent is selected from a group consisting of an anthracycline, cytarabine, a purine analog, sorafenib, gemtuzumab ozogamicin, rituximab, and combinations thereof.
24. The method of claim 19 , wherein the at least one agent is administered sequentially or simultaneously.
25. The method of claim 19 , wherein the at least one agent is co-formulated or co-packaged.
26. A method for modulating GSPT1 activity in at least one cell, comprising a step of contacting the at least one cell with an effective amount of at least one compound of claim 1 , or a pharmaceutically acceptable salt thereof.
27. The method of claim 26 , wherein contacting is via administration to a mammal.
28. The method of claim 27 , wherein the mammal has been diagnosed with a need for modulating GSPT1 activity or for amelioration or alleviation of a cancer characterized by GSPT1 activity prior to the administering step.
29. The method of claim 27 , wherein the compound inhibits cell proliferation with an IC50 of less than about 10 μM when determined in a cell viability assay using MV4-11 cells as described herein;
wherein the compound exhibits cereblon binding with an IC50 of less than about 10 μM using a fluorescence polarization assay as described herein; or
wherein the compound inhibits cell proliferation with an IC50 of less than about 20 μM when determined in a cell viability assay using GSPT1 HiBit tagged cell.